Home › Funds › Kynam Capital Management, LP › VRDN

Kynam Capital Management, LP position in VRDN

OBSIDIAN THERAPEUTICS INC · Health Care

Kynam Capital Management, LP reported holding 6,453,877 shares of VRDN (OBSIDIAN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$118.6M, representing 6.55% of its reported portfolio and ranking #6 among its reported holdings. Kynam Capital Management, LP has disclosed VRDN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)6.45M sh
Reported value held$118.56M
Portfolio Weight6.55%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Kynam Capital Management, LP's VRDN position evolved

Kynam Capital Management, LP first disclosed a stake in VRDN in Q3 2023 at 699,681 shares (US$10.7M). The position peaked in Q2 2026 at 6,453,877 shares, worth US$118.6M. Across 12 filings, Kynam Capital Management, LP increased the stake 6 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 6,453,877 shares valued at US$118.6M — an increase of 4,112,225 shares quarter over quarter.. Notable position changes include a 78% trim in Q1 2024 (shares fell 26% over the following quarter), a 1207% increase in Q2 2024 (shares rose 75% over the following quarter), a 176% increase in Q2 2026 (shares rose 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 699.68K $10.73M New
Q4 2023 607.91K $13.24M Reduce
Q1 2024 133.88K $2.34M Reduce
Q2 2024 1.75M $22.77M Add
Q3 2024 2.51M $57.13M Add
Q4 2024 3.33M $63.76M Add
Q1 2025 4.70M $63.36M Add
Q2 2025 4.43M $61.90M Reduce
Q3 2025 4.43M $95.55M Hold
Q4 2025 1.47M $45.76M Reduce
Q1 2026 2.34M $45.80M Add
Q2 2026 6.45M $118.56M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRDN and 13F data

VRDN (OBSIDIAN THERAPEUTICS INC) is a Health Care company. 36 other funds we track also report a position in VRDN — the largest reported positions include Bellevue Group AG (US$123.7M), Paradigm Biocapital Advisors LP (US$123.5M), Fairmount Funds Management LLC (US$93.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRDN

All VRDN fund holders →

FAQ

How long has Kynam Capital Management, LP held VRDN?

Kynam Capital Management, LP has disclosed VRDN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Kynam Capital Management, LP's current position in VRDN?

As of Q2 2026, Kynam Capital Management, LP holds 6.45M shares of VRDN (OBSIDIAN THERAPEUTICS INC), valued at $118.56M, representing 6.55% of its reported portfolio and ranking #6.

Has Kynam Capital Management, LP been buying or selling VRDN?

In the latest 13F filing (Q2 2026), Kynam Capital Management, LP increased its position in VRDN. The position peaked in Q2 2026 at 6.45M shares.

Which other funds hold VRDN?

Other major institutional holders of VRDN include Bellevue Group AG, Paradigm Biocapital Advisors LP, Fairmount Funds Management LLC, among 36 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.